Dr Reddys Laboratories (RDY) Liabilities and Shareholders Equity (2009 - 2026)

Dr Reddys Laboratories (RDY) has reported Liabilities and Shareholders Equity for 10 consecutive years, with $6.2 billion the latest figure, recorded in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 6.98% year-over-year to $6.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.6 billion (up 15.76% YoY) and the FY2026 annual result came in at $6.2 billion, up 6.98% from the prior year.
• Liabilities and Shareholders Equity climbed to $6.2 billion in Q1 2026 per RDY's latest filing, from $5.8 billion in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for RDY reached as high as $6.2 billion in Q1 2026 and fell as low as $3.9 billion in Q1 2022.
• A 5-year average of $4.9 billion and a median of $4.6 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity increased 1.45% — and 2025, when it grew 24.13%.
• Year by year, Liabilities and Shareholders Equity stood at $3.9 billion in 2022, then grew by 1.45% to $3.9 billion in 2023, then increased by 18.74% to $4.6 billion in 2024, then climbed by 24.13% to $5.8 billion in 2025, then gained by 6.98% to $6.2 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $6.2 billion, $5.8 billion, and $4.6 billion for Q1 2026, Q1 2025, and Q1 2024 respectively.